Bortezomib (PS-341)

Catalog No.S1013 Synonyms: LDP-341, MLM341

Bortezomib (PS-341) Chemical Structure

Molecular Weight(MW): 384.24

Bortezomib (PS-341) is a potent 20S proteasome inhibitor with Ki of 0.6 nM. It exhibits favorable selectivity towards tumor cells over normal cells.

Size Price Stock Quantity  
USD 70 In stock
USD 270 In stock
USD 670 In stock
Bulk Discount
Bulk Inquiry

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 154 Publications

25 Customer Reviews

  • Immunoblot analysis of cell lysates from the indicated cell lines treated with GNE-6776 (2 μ M for 18 h), either alone or in combination with a UAE1 inhibitor MLN-7243 (5 μ M for 45 min) or the proteasome inhibitor bortezomib (5 μ M for 45 min) as indicated.

    Nature, 2017, 550(7677):534-538. Bortezomib (PS-341) purchased from Selleck.

    Indisulam dependent degradation of RBM39 can be blocked by bortezomib, a proteasome inhibitor. Cells were pretreated with indicated concentrations of bortezomib for 2 hours, followed by 6 hours of treatment with 2 μM indisulam. The effect of bortezomib is attenuated in a bortezomib resistant cell line.

    Science, 2017, eaal3755. Bortezomib (PS-341) purchased from Selleck.

  • Wild-type mice fed as indicated were injected with vehicle (10% DMSO, pH 7.4 PBS) or bortezomib (5 mg/kg bodyweight). Livers were collected 16 hr later for quantitative PCR analysis of indicated genes (n = 4–5). *p < 0.05 bortezomib effect and #p < 0.05 Chol-Diet effect by two-way ANOVA.

    Cell, 2017, 171(5):1094-1109. Bortezomib (PS-341) purchased from Selleck.

    Effect of different proteasome inhibitors on dysferlin expression and on membrane resealing in cultured primary myoblasts. Primary myoblasts from patient 2 harboring a homozygous Arg555Trp DYSF mutation that were treated with the indicated amounts of bortezomib for 24 hours. Western blots of protein extracts were stained with anti-dysferlin antibodies and with anti–a-tubulin antibody as loading control.

    Sci Transl Med 2015 6(250), 250ra112. Bortezomib (PS-341) purchased from Selleck.

  • Pharmacologic inhibition of the proteasome blocks proplatelet formation in murine and human megakaryocytes. Human megakaryocytes were pretreated with vehicle or bortezomib, and megakaryocytes producing proplatelets (PP) were examined. Shown are representative transmission images and representative confocal images with wheat germ agglutinin (WGA; red) and phalloidin (green) staining. Scale bars: 50 um.

    J Clin Invest 2014 124(9), 3757-66. Bortezomib (PS-341) purchased from Selleck.

    Effects of NF-kB inhibition on cell proliferation and apoptosis in Foxp3cKO prostate. A. Top left panels: Representative H&E staining of PIN lesions in ventral prostates of 60-week-old PBS- or bortezomib-treated Foxp3cKO littermates. Scale bar, 50 祄. Right graph: Quantification of Ki67-positive cells identified by IHC analysis (bottom left panels) as a measure of cell proliferation, performed with Scion Image software. Horizontal lines represent the average values. The p value was determined by two-tailed t test. B. Representative western blots showing p65 and nuclear p65 (N-p65) expression in prostates at 12 hours after LPS injection in 45-week-old PBS- or bortezomib-treated mice. C. Quantification of Bcl2l1 and Traf1/2 mRNA expression as a percentage of Hprt expression measured in microdissected mouse prostate epithelial cells by qPCR at 12 hours after LPS injection in 45-week-old PBS- or bortezomib-treated mice. Horizontal lines represent the average values. The p values were determined by two-tailed t test. D. Left panels: Representative images of TUNEL assays performed on prostates from PBS- or bortezomib-treated mice at 60 weeks of age. Insets show the apoptotic cells (green) in prostate glands. Scale bar, 100 祄. Right graph: Quantification of apoptotic cells in the ventral and dorsolateral prostates of PBS- or bortezomib-treated mice at 45 and 60 weeks of age. Horizontal lines represent the average values. The p value was determined by two-tailed t test. cKO, PB4-Cre4+Foxp3flox/y; wks, weeks; B/P, ratio of the mean value from bortezomib-treated mice to the mean value in PBS-treated mice. All experiments were repeated two times. Wks, weeks.

    Cancer Res 2015 75(8), 1714-24. Bortezomib (PS-341) purchased from Selleck.

  • Immunofluorescence showing HDAC4 localization in mouse primary osteoblasts treated with vehicle or PTH alone or in the presence of bortezomib. Primary osteoblasts treated with vehicle, PTH, or PTH plus bortezomib for 2 h using anti-HDAC4 and anti-b-actin antibodies.

    J Cell Biol 2014 205(6), 771-80. Bortezomib (PS-341) purchased from Selleck.

    Inhibition of proteasome and lysosome or silencing of VCP and co-factors lead to the accumulation of OP-puro-labeled DRIPs adjacent to or within SGs. HeLa cells were co-treated for 45 min with OP-puro and arsenite (Ars.); where indicated, cells were pretreated with bortezomib (Bort.) overnight and/or ammonium chloride (NH4Cl) for 2 h 15 min. Cells were fixed and labeled with Alexa594-Azide and anti-TIA-1.

    Cell Death Differ 2014 21(12), 1838-51. Bortezomib (PS-341) purchased from Selleck.

  • Immunofluorescence analysis for Ser536 p-NF-κB cellular localization of RS4;11cells treated with CX-4945 (5 μM) and bortezomib (2.5 nM) either alone or in combination. Cells were treated, collected at 22 h and reacted with an antibody to Ser536 p-NF-κB which was revealed by a Cy3-conjugated secondary antibody. DAPI was used to label nuclei.

    Oncotarget, 2015, 51: S659-S660. Bortezomib (PS-341) purchased from Selleck.

    Control wild-type and Fmn2–/–oocytes observed at different stages of meiotic maturation [prophase I (Pro I), NEBD, 3 hours and 8 hours after NEBD] using anti-Fmn2. wt + Bortezo, wild-type oocytes treated with 0.1μM Bortezomib for 90 minutes before fixation. All oocytes were observed using the same settings and the images treated the same way (three independent experiments). Red arrows indicate cortical labeling. Scale bar: 10μm.

    Development 2011 138, 2903-2908. Bortezomib (PS-341) purchased from Selleck.

  • Cell viability of HCT116 cells treated with a single drug or with the addition of leucovorin.

    Sci Rep, 2017, 7(1):682. Bortezomib (PS-341) purchased from Selleck.

    (B–C) LNCaP (B) and LNCaP-AI (C) cells were transiently transfected with sPLA2-IIa(-800)-Luc (0.5 μg). The cells were then treated with Erlotinib (20 μM), Gefitinib (20 μM), Lapatinib (20 μM), CI-1033 (8 μM), LY294002 (20 μM) and Bortezomib (20 μM) without or with EGF (100 ng/ml) for 24 h. Luciferase assay was performed according to a standard protocol with Renilla luciferase as an internal control. Data are presented as the mean (±SD) of duplicate values of a representative experiment that was independently repeated for five times.

    Carcinogenesis 2010 31, 1948–1955. Bortezomib (PS-341) purchased from Selleck.

  • LNCaP-AI cells were starved in 1% stripped medium for 24 h. The cells were then treated with Erlotinib (20 μM), Gefitinib (20 μM), Lapatinib (20 μM), CI-1033 (8 μM), LY294002 (20 μM) and Bortezomib (20 μM) for 24 h. Cell culture medium was collected from each sample and subjected to ELISA for sPLA2-IIa. The condition medium samples were diluted 10 times for ELISA. Average of duplicate samples was converted to nanogram per milliliter against standard curve. The data represent one of five repeated experiments.

     

     

    Carcinogenesis 2010 31, 1948–1955. Bortezomib (PS-341) purchased from Selleck.

    Western blot of extracts of infected cells treated with different proteasome inhibitors at different concentrations, reacted with the indicated antibodies. p53 was used to monitor proteasome inhibition, and actin was used as a loading control.

     

     

    J Virol 2011 85, 2781–2792. Bortezomib (PS-341) purchased from Selleck.

  • Time window treatment with proteasome inhibitors. (A) Scheme of the experiment performed with MA104 cells exposed to virus (OSU; MOI, 3) for 1 h and analyzed at the starting point and endpoint of the indicated time window treatments with DMSO, MG132, or bortezomib. (B) Western blot of cellular lysates derived from cells infected for the indicated time periods and treated with the proteasome inhibitors or DMSO. NI, noninfected cells. Blots were reacted with the indicated antibodies; p53 was used to monitor proteasome inhibition, and actin was used as a loading control.

    J Virol 2011 85, 2781–2792. Bortezomib (PS-341) purchased from Selleck.

    Fluorescence analysis of viroplasm formation on NSP5-EGFP cells infected with rotavirus (OSU; MOI, 3) and treated or not treated with MG132 (10 M) or bortezomib (10 M) at different times p.i., as indicated. Cells were analyzed at the starting points (1 h, 3 h, 5 h, 7 h) and endpoints (9 h) of the inhibitor’s window treatment.

     

     

    J Virol 2011 85, 2781–2792. Bortezomib (PS-341) purchased from Selleck.

  • Quantification of the accumulation of viroplasms in infected NSP5 -EGFP/MA104 cells. At different times p.i., cells were treated for 4 h with DMSO or the indicated proteasome inhibitor and the number of viroplasms/cell was quantified at the starting (1 h, 3 h, 5 h; white bars) and endpoints (5 h, 7 h, 9 h) of treatment.

     

     

    J Virol 2011 85, 2781–2792. Bortezomib (PS-341) purchased from Selleck.

    PS-341 impairs FPV replication in A549 cells. (A and B)A549 cells were either pretreated for 1 h with different concentrations of PS-341 or with solvent only or were left untreated. Then, cells were infected with FPV at an MOI of 0.001 (A) or 0.05 (B). After virus inoculation cells were posttreated with different concentrations of PS-341. (A) At 24 h p.i. supernatants were obtained and progeny virus titers were measured by standard plaque assay. (B)Proteasome activity and the ability of PS-341 to inhibit the proteasome was determined 24 h p.i. (C) A549 cells were pretreated with 50 nM PS-341 or solvent or left untreated for 1 h. Afterwards cells were infected with FPV at an MOI of 0.0005. Subsequent to virus inoculation cells were posttreated with 50 nM PS-341 or solvent or left untreated. After the indicated times p.i.supernatants were obtained and progeny virus titers were determined by standard plaque assay. Arrow bars in all experiments represent standard deviations of three independent experiments.

    J Virol 2010 84, 9439–9451. Bortezomib (PS-341) purchased from Selleck.

  • Early steps of viral replication within the first replication cycle are affected. (A) For time-of-addition kinetics analysis, A549 cells were either left untreated or were pretreated for 10 h or 1 h with 50 nM PS-341 before infection and additionally posttreated after infection. Cells were infected with FPV at an MOI of 0.005. After virus inoculation cells were posttreated with 50 nM PS-341. Then the proteasome inhibitor was added after virus inoculation (10 h, 1 h, and 30 min) or it was added at the different times p.i. as indicated (1 h, 2 h, 4 h, 6 h, and 8 h; cells were not pretreated before infection). At 9 h p.i. supernatants were obtained and progeny virus titers were determined by standard plaque assay. Shown is one representative experiment out of three independent experiments. (B) A549 cells were pretreated with 50 nM PS-341 or left untreated for 1 h. Afterwards cells were infected with avian FPV or human PR8 at an MOI of 1. Subsequent to virus inoculation cells were posttreated with 50 nM PS-341 or left untreated. After the indicated times p.i. cells were lysed and analyzed by Western blotting for accumulation of viral proteins polymerase PB1 and matrix protein M1. Cellular protein ERK2 served as a control to demonstrate equal amounts of protein loading. Shown is one representative blot out of three independent experiments.

     

     

    J Virol 2010 84, 9439–9451. Bortezomib (PS-341) purchased from Selleck.

    A549 cells were treated with PS-341 at 50 nM for the indicated times or left untreated. Western blotting was performed with total cell lysates, using phospho-specific antibodies against JNK and the transcription factors c-Jun and ATF-2 or loading controls, respectively.

     

     

    J Virol 2010 84, 9439–9451. Bortezomib (PS-341) purchased from Selleck.

  • The stable cell line HepAD38 was incubated for 18 h in the presence of the indicated amount of Bortezomib. The medium was removed and replaced by medium containing Bortezomib dissolved in PBS. In case of the control cells the same amount of PBS was added to the medium. 4 h later this procedure was repeated and again 14 h later the supernatant was collected. The amount of viral particles was quantified by real time PCR. HBV-genome quantification was done using COBAS® AmpliPrep/COBAS® TaqMan® HBV test (Roche Diagnostics GmbH, Mannheim, Germany) according to the manufacturer’s instructions. The assay shows relative values (the value for untreated control cells was arbitrarily set as 1) that are based on three independent experiments. The cell viability was analyzed by MTT assays. For does up to 50 nM no significant effect on cell viability was observed within 18h, for 100 nM the proportion of metabolically active cells was reduced to 83%.

    J Biol Chem 2010 285, 41074-41086. Bortezomib (PS-341) purchased from Selleck.

    HLC-1 cells were treated with IFN-gamma (30 ng/ml) and Bortezomib (0-10 nM) for 3 h. After washing with PBS, the cells were cultured for another 45 h in the fresh medium. After 48 h incubation, PD-L1 expression was analysed by flow cytometry (n =3).

    Int Immunopharmacol, 2018, 54:39-45. Bortezomib (PS-341) purchased from Selleck.

  • Proteasome inhibition effect on biotinylation of MHC-Iα. (a) WB-ra of cellular extracts of HEK293 cells co-transfected with BAP-MHC-Ia and cyt-BirA (control) and, where indicated, with US2 or US11 in the absence (2) or presence of MG132 (MG; 50 μM for 4 h) or Bortezomib(Bort.; 50 μM for 4 h).

    PLoS One 2011 6, e23712. Bortezomib (PS-341) purchased from Selleck.

     

    KKU-M213 was treated with BTZ as indicated. Total cell lysate ( a) and nuclear extract (b) were prepared. Actin and γ -tubulin were loading controls for total and nuclear proteins, respectively.

    2011 Mireia Vila Gasull University of Porto. Bortezomib (PS-341) purchased from Selleck.

  • Mireia Vila Gasull University of Porto. 2011;Mireia Vila Gasull . Bortezomib (PS-341) purchased from Selleck.

Purity & Quality Control

Choose Selective Proteasome Inhibitors

Biological Activity

Description Bortezomib (PS-341) is a potent 20S proteasome inhibitor with Ki of 0.6 nM. It exhibits favorable selectivity towards tumor cells over normal cells.
Targets
20S proteasome [1]
(Cell-free assay)
0.6 nM(Ki)
In vitro

Bortezomib, a boronic acid dipeptide, is a highly selective, reversible inhibitor of the 26S proteasome which primarily functions in the degradation of mis-folded proteins and is essential for the regulation of the cell cycle. Exposure to Bortezomib has been shown to stabilize p21, p27, and p53, as well as the proapoptotic Bid and Bax proteins, caveolin-1, and inhibitor κB-α, which prevents activation of nuclear factor κB-induced cell survival pathways. Bortezomib also promotes the activation of the proapoptotic c-Jun-NH2 terminal kinase, as well as the endoplasmic reticulum stress response. Alteration of the levels of these cellular proteins leads to inhibition of proliferation, migration, and promotion of apoptosis of cancer cells. [2] Bortezomib is shown to penetrate into cells and inhibit proteasome-mediated intracellular proteolysis of long-lived proteins with a concentration that inhibits 50% of the proteolysis of ∼0.1 μM. The average growth inhibition of 50% value for Bortezomib across the entire panel of 60 cancer cell lines derived from multiple human tumors from the US National Cancer Institute (NCI) is 7 nM. Treatment of PC-3 cells with Bortezomib (100 nM) for 8 h results in the accumulation of cells in G2-M, with a corresponding decrease in the number of cells in G1. Bortezomib kills PC-3 cells at 24 and 48 hr with IC50 of 100 and 20 nM, respectively. Bortezomib induces nuclear condensation at 16–24 hr after treatment. Bortezomib treatment leads to PARP cleavage in a time-dependent manner with concentrations as low as 100 nM being effective at 24 hr. [1]
Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
MCF-7 M33scmN6fG:2b4jpZ{BCe3OjeR?= M2TmflUxKM7:TR?= MX60PEBp NUDSbmpRTE2VTx?= NFK1RXJMcWyuczDj[YxteyCkeTDtc5JmKHSqYX6gPVkm M330T|ExPDl7NkSz
OVCA 429 MoD6SpVv[3Srb36gRZN{[Xl? MoLxN|AxKG6P NWryVlExPDhiaB?= MmPHSG1UVw>? Mnz1SIl{enWydIOgbY51[WO2IH31cJRq[2WubIXsZZIhfHWvb4Kgd5Bp\XKxaXTz NHfKNogyODl7OUe2Oi=>
RPMI8226 NGHmVXJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH:0WIoyODBibl2= NYfzXll3PDhiaB?= MVPEUXNQ MXvJR|UxRTNyIH7N Mo[0NVE{ODZ2OEm=
Dox40 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4TNclExOCCwTR?= NVzlVHBFPDhiaB?= M2TGTGROW09? NXnnPHVlUUN3ME20NEBvVQ>? NIrTZnAyOTNyNkS4PS=>
MR20 NH3DT|JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUSxNFAhdk1? MnTHOFghcA>? M1rt[2ROW09? MWrJR|UxRTJyIH7N NUn1THBEOTF|ME[0PFk>
LR5 MojVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3rydFExOCCwTR?= M{TnOlQ5KGh? NGnNXpJFVVOR M{jCPWlEPTB;MkCgcm0> MX:xNVMxPjR6OR?=
U266 NEnxdWpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoTNNVAxKG6P NELjZ5o1QCCq NHuw[2xFVVOR NI\RNGdKSzVyPUOgcm0> M3\nclEyOzB4NEi5
IM-9 M2r3WWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUCxeYdCOTByIH7N NUnlfVQ1PDhiaB?= M1zxcGROW09? M2TKfmlEPTB;NjDuUS=> NFLVdIkyOTNyNkS4PS=>
Hs Sultan NGOzPY9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVnve3pqOTByIH7N MoDyOFghcA>? MlrkSG1UVw>? MknVTWM2OD1{MDDuUS=> MVGxNVMxPjR6OR?=
PAM-LY2 MmXMSpVv[3Srb36gRZN{[Xl? MVKxNFAhdk1? Mn;hNVIhcA>? NVLYOm1HTE2VTx?= Mmj1TY5pcWKrdIOgUmYu|rqEIHHjeIl3[XSrb36= NV;SfotYOTF|NUC5NVM>
PAM 212 M4DVfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXLo[3ZwOTByIH7N MWK3NkBp NGjCVVVFVVOR NUTrRpQ{UW6qaXLpeJMh[2WubDD2bYFjcWyrdIm= M3;QUlEyOzVyOUGz
PAM-LY2 NVfCSWw4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHG2W5cyODBibl2= NVPZUJdVPzJiaB?= MkHlSG1UVw>? MVPJcohq[mm2czDj[YxtKH[rYXLpcIl1gQ>? NFvjXo4yOTN3MEmxNy=>
B4B8 NYrOU3FST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mk[5NVAxKG6P MWG3NkBp MlXpSG1UVw>? NHPuWXhKdmirYnn0d{Bk\WyuII\pZYJqdGm2eR?= MmLtNVE{PTB7MUO=
B7E3 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIrMVIEyODBibl2= NVrLe|d[PzJiaB?= NGr1boVFVVOR NFLNT3BKdmirYnn0d{Bk\WyuII\pZYJqdGm2eR?= NVfoV2V6OTF|NUC5NVM>
UM-SCC-9 NHz4UpNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUCxNFAhdk1? MUO3NkBp Mn64SG1UVw>? MkjxTY5pcWKrdIOgZ4VtdCC4aXHibYxqfHl? MlvvNVE{PTB7MUO=
UM-SCC-11B NGewUXJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXvQcFIyOTByIH7N NUjtO3VVPzJiaB?= NW\zRXc6TE2VTx?= MlvyTY5pcWKrdIOgZ4VtdCC4aXHibYxqfHl? M1vyNVEyOzVyOUGz
H460 NFzEeYxHfW6ldHnvckBCe3OjeR?= MWGxNEDPxE1? MUWyOEBp NV61T2wxTE2VTx?= MVPJcoR2[2W|IFLjcE0zKHCqb4PwbI9zgWyjdHnvckBidmRiY3zlZZZi\2ViY3;ydoVt[XSnZDD3bZRpKEd{LV2gdIhie2ViYYLy[ZN1 NX;he5JrOTJ2OUKxNVc>
U266 M4nEWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIrhe2I2ODBibnevcYw> MnTnOFghcA>? MoHhSG1UVw>? MkDNTY5pcWKrdIOgZ4VtdCCpcn;3eIg> MkiyNVI3OzF4MUm=
ARH77 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M37BdlUxOCCwZz;tcC=> MlLnOFghcA>? NH63RWpFVVOR NFnmOIFKdmirYnn0d{Bk\WyuIHfyc5d1cA>? NEHJUJkyOjZ|MU[xPS=>
WAD-1 M2LDeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGq1ZXE2ODBibnevcYw> M3juPFQ5KGh? M4H5eWROW09? MmfpTY5pcWKrdIOgZ4VtdCCpcn;3eIg> MkTnNVI3OzF4MUm=
U266/LR7 NV[ySlZXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX61NFAhdmdxbXy= MXG0PEBp M3;yVmROW09? NIPTb4ZKdmirYnn0d{Bk\WyuIHfyc5d1cA>? MYixNlY{OTZzOR?=
U266/dox4 NF7xeWlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mo[yOVAxKG6pL33s NWXyXIo{PDhiaB?= M4nUNGROW09? M{LSfmlvcGmkaYTzJINmdGxiZ4Lve5Rp NYnHenJGOTJ4M{G2NVk>
RPMI8226/LR5 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NELTNHo2ODBibnevcYw> NX\LUG9LPDhiaB?= MYLEUXNQ NEXE[IxKdmirYnn0d{Bk\WyuIHfyc5d1cA>? M2n2e|EzPjNzNkG5
H460 NWHhVJA2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV2xNEDPxE1? M17KOlczKGh? NWDGZ|dqTE2VTx?= NV3nNot1UUN3ME2xNFAhdk1? MnOzNVI3OzF4MkC=
H358 MkfuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml\UNVAh|ryP MWG3NkBp NVT0WmdRTE2VTx?= MXLJR|UxRTdyIH7N M{nwUVEzPjNzNkKw
H322 M{T4Tmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXnE[G97OTBizszN NWPXdIdpPzJiaB?= NYD0fol2TE2VTx?= NGf1bHZKSzVyPU[yNEBvVQ>? NIrEO4QyOjZ|MU[yNC=>
H460 NX;0fmNyTnWwY4Tpc44hSXO|YYm= NUnLfFF{OTByIH7N NUnWTJJXOjRiaB?= MnfOSG1UVw>? NFHhTFJKdmS3Y3XzJGczNU1vcHjhd4Uh[XK{ZYP0JIFv\CC2dXL1cIlvKGG|c3XtZox6NWSrc3Hzd4Vu[my7 MUOxNlY{OTZ{MB?=
LNCap-Pro5 M3fXOWZ2dmO2aX;uJGF{e2G7 M1;XSFEh|ryP Mn\nOEBp MkeySG1UVw>? M17FTXN1[WKrbHn6[ZMheDV| MXyxOFYyOjV|Mh?=
T29 MV3BdI9xfG:|aYOgRZN{[Xl? MUK1NEBvVQ>? NIHheIE1QCCqIB?= NHzyO2JFVVOR MYLJcoR2[2W|IHPlcIwh[XCxcITvd4l{ MkHINVY4PzhzN{m=
T29Kt1 MUnBdI9xfG:|aYOgRZN{[Xl? NY\Yb20xPTBibl2= M4PnWVQ5KGhi MnG4SG1UVw>? MXLJcoR2[2W|IHPlcIwh[XCxcITvd4l{ MnPJNVY4PzhzN{m=
HCT116 MnXSRZBweHSxc3nzJGF{e2G7 MlK0OVAhdk1? MV60PEBpKA>? NFTjSHJFVVOR M{P0TWlv\HWlZYOgZ4VtdCCjcH;weI9{cXN? MVyxOlc4QDF5OR?=
HKe-3 NGTBS|lCeG:ydH;zbZMhSXO|YYm= NXrwZ2FiPTBibl2= NWXud3R4PDhiaDC= M3zEU2ROW09? M{PXNGlv\HWlZYOgZ4VtdCCjcH;weI9{cXN? M4TZVVE3Pzd6MUe5
NB-1691 NYfoPYh5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWOxJO69VQ>? NHuyZnI4OiCq MYXJcohq[mm2czDj[YxtKHC{b3zp[oVz[XSrb36geI8hPSV? M2P4VFE4Pjh7Nki0
CHLA-255 M4njT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1jYeFEh|ryP M2XtflczKGh? NY\GbYZMUW6qaXLpeJMh[2WubDDwdo9tcW[ncnH0bY9vKHSxIEKl M13KdFE4Pjh7Nki0
SK-N-AS MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVmxJO69VQ>? MUO3NkBp MljpTY5pcWKrdIOgZ4VtdCCycn;sbYZmemG2aX;uJJRwKDFyJR?= MUOxO|Y5QTZ6NB?=
NB-1691 NY\NXZdOTnWwY4Tpc44hSXO|YYm= NH7Sbm8yOCCwTR?= NHraR5QzPCCq NYjBSnNCW2mpbnnmbYNidnSueTDy[YR2[2W|IHPlcIx{KGmwIITo[UBIOC:JMTDwbIF{\Q>? NXi3OG9UOTd4OEm2PFQ>
CHLA-255 NVnOd2N{TnWwY4Tpc44hSXO|YYm= NWLqbXhXOTBibl2= Ml7qNlQhcA>? MlT5UY9l\XO2bImgdoVlfWOnczDj[YxteyCrbjD0bIUhTzBxR{GgdIhie2V? NYHVNlhLOTd4OEm2PFQ>
RPMI 8226 MnH6SpVv[3Srb36gRZN{[Xl? MVmyNEBvVQ>? NYq2R3Y5QCCq MXPTbYdvcW[rY3HueIx6KGWwaHHuZ4V{KE6ILd86RkBi[3Srdnn0fS=> M1vJVVE6PDN4MEWw
MM.1S MVLGeY5kfGmxbjDBd5NigQ>? NHrLeG4zOCCwTR?= NFPWSJE5KGh? MUnTbYdvcW[rY3HueIx6KGWwaHHuZ4V{KE6ILd86RkBi[3Srdnn0fS=> Mk\rNVk1OzZyNUC=
U266 MWPGeY5kfGmxbjDBd5NigQ>? NETodVAzOCCwTR?= NFfxb|M5KGh? MUnTbYdvcW[rY3HueIx6KGWwaHHuZ4V{KE6ILd86RkBi[3Srdnn0fS=> MXyxPVQ{PjB3MB?=
OPM1 MlLTSpVv[3Srb36gRZN{[Xl? M{PYPFIxKG6P M2q1WFghcA>? NEixW5NUcWewaX\pZ4FvfGy7IHXubIFv[2W|IF7GMe67SiCjY4Tpeol1gQ>? M3u1TFE6PDN4MEWw
INA6 MlTXSpVv[3Srb36gRZN{[Xl? NVz4c|AyOjBibl2= M3TXR|ghcA>? MYTTbYdvcW[rY3HueIx6KGWwaHHuZ4V{KE6ILd86RkBi[3Srdnn0fS=> M324bVE6PDN4MEWw
OPM2 NIniT3VHfW6ldHnvckBCe3OjeR?= NV7tc2k{OjBibl2= MUG4JIg> MVTTbYdvcW[rY3HueIx6KGWwaHHuZ4V{KE6ILd86RkBi[3Srdnn0fS=> NIPnboEyQTR|NkC1NC=>
RPMI 8226 NWq1ZYRwTnWwY4Tpc44hSXO|YYm= MXuyNEBvVQ>? NHTuNVY5KGh? M4HGUGlv\HWlZYOgSG5CKHO7boTo[ZNqew>? Mo\GNVk1OzZyNUC=
BaF/3 M1PIeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVmxNFAhdk1? MVS0PEBp NVHUU3Y{UUN3ME22MlIhdk1? NYLYUmI1OjB|MEW2PVI>
BaF/3-p210 M3ThbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUfGOnZbOTByIH7N M4\Tb|Q5KGh? M1rhWmlEPTB;ND63JI5O M1rUcFIxOzB3Nkmy
TCC-S MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVKxNFAhdk1? M2nSPVQ5KGh? NV65[|lMUUN3ME2yMlghdk1? NFXjXGIzODNyNU[5Ni=>
BaF/3 NWqyOZp4TnWwY4Tpc44hSXO|YYm= MofjOkBvVQ>? NXjOTYJPPDhiaB?= NF\Fb2dKdmS3Y3XzJIEh\3KnYYSgS|Eh[2WubD3jfYNt\SCjcoLld5Q> Mo\RNlA{ODV4OUK=
BaF/3-p210 M1L5OGZ2dmO2aX;uJGF{e2G7 NYLW[Yh[PiCwTR?= NHyxNHI1QCCq NXm0b2tkUW6mdXPld{BiKHOuaXfoeEBIOSClZXzsMYN6[2ynIHHydoV{fA>? MojlNlA{ODV4OUK=
BaF/3-p210 NGPvb4RHfW6ldHnvckBCe3OjeR?= M3Tye|Yhdk1? M2\rWlI1KGh? MWLS[YR2[2W|IITo[UBxcG:|cHjvdplt[XSrb36gZY5lKHSqZTDhZ5Rqfmm2eTDv[kBT[g>? M4jUR|IxOzB3Nkmy
Raji MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYrzZ4FZOSEQvF2= MX:yOEBp MXjS[YR2[2W|IHPlcIwhfmmjYnnsbZR6yqB? MVyyNVE4ODl6OB?=
LCL-1 NULhUYlST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVWxJO69VQ>? M4XmT|I1KGh? NWLod5lCWmWmdXPld{Bk\WyuII\pZYJqdGm2edMg NGX5bY8zOTF5MEm4PC=>
LCL-2 MlLxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWfiOlVTOSEQvF2= M1;T[FI1KGh? NIDYfWNT\WS3Y3XzJINmdGxidnnhZoltcXS7wrC= M{DPeFIyOTdyOUi4
BJAB Mny2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWSxJO69VQ>? MlrxNlQhcA>? NHyw[IVT\WS3Y3XzJINmdGxidnnhZoltcXS7wrC= NXrjNo1TOjFzN{C5PFg>
SNT-13 NGrGb5FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml\JNUDPxE1? MmDNNlQhcA>? Mk\lVoVlfWOnczDj[YxtKH[rYXLpcIl1gcLi M1jH[VIyOTdyOUi4
SNT-16 MlOxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHzobVAyKM7:TR?= NE\COpgzPCCq MWnS[YR2[2W|IHPlcIwhfmmjYnnsbZR6yqB? M{\uUVIyOTdyOUi4
Jurkat M3\ScGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NY\HZm9EOSEQvF2= M3\yelI1KGh? M{Gz[XJm\HWlZYOgZ4VtdCC4aXHibYxqfHoEoB?= NVPONlZmOjFzN{C5PFg>
KAI-3 NHnKdnJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M13peFEh|ryP NXH6W4ZxOjRiaB?= NYrkVI9WWmWmdXPld{Bk\WyuII\pZYJqdGm2edMg MY[yNVE4ODl6OB?=
SNK-6 NVLVNFFVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWmxJO69VQ>? NVfDbXZ{OjRiaB?= NUC4Om8zWmWmdXPld{Bk\WyuII\pZYJqdGm2edMg MYWyNVE4ODl6OB?=
KHYG-1 M4TNTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mo\6NUDPxE1? MkTaNlQhcA>? MoPSVoVlfWOnczDj[YxtKH[rYXLpcIl1gcLi NISwcJYzOTF5MEm4PC=>
SNT-16 MUTBdI9xfG:|aYOgRZN{[Xl? M2f5c|Eh|ryP M2fWNFYhcA>? MWjJcoR2[2W|IHPlcIwh[XCxcITvd4l{ M3HTfVIyOTdyOUi4
Jurkat NGP1NYRCeG:ydH;zbZMhSXO|YYm= M4f6[VEh|ryP NGjOXlE3KGh? MlXaTY5lfWOnczDj[YxtKGGyb4D0c5Nqew>? NYjLdFJMOjFzN{C5PFg>
KAI-3 MoHkRZBweHSxc3nzJGF{e2G7 M3PocFEh|ryP M2rORVYhcA>? NGPVem5KdmS3Y3XzJINmdGxiYYDvdJRwe2m| MVGyNVE4ODl6OB?=
KHYG-1 M4HNWmFxd3C2b4Ppd{BCe3OjeR?= MUmxJO69VQ>? MYS2JIg> MUjJcoR2[2W|IHPlcIwh[XCxcITvd4l{ NUL4eZlKOjFzN{C5PFg>
SNT-13 NInKV5FCdnSrdnnyZYwhSXO|YYm= MVexJO69VQ>? NISzeW4zPCCq MmjlTY5lfWOnczDsfZRq[yCrbn\lZ5Rqd25ib3[gSWJX NVvaTIw4OjFzN{C5PFg>
SNT-16 MkL5RY51cX[rcnHsJGF{e2G7 M2HlR|Eh|ryP Mn\RNlQhcA>? M2nCN2lv\HWlZYOgcJl1cWNiaX7m[YN1cW:wIH;mJGVDXg>? MWqyNVE4ODl6OB?=
KAI-3 NIjMVHZCdnSrdnnyZYwhSXO|YYm= NU[zemxmOSEQvF2= NUfyW5cyOjRiaB?= MmLBTY5lfWOnczDsfZRq[yCrbn\lZ5Rqd25ib3[gSWJX M1[0XFIyOTdyOUi4
SNK-6 NHnTe4tCdnSrdnnyZYwhSXO|YYm= MUSxJO69VQ>? M1Hxc|I1KGh? NIraVIlKdmS3Y3XzJIx6fGmlIHnu[oVkfGmxbjDv[kBGSlZ? MmPGNlEyPzB7OEi=
RAW 264.7 NYjodIl3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn6xNVAxKG6P NHrFS3Y1QCCq NVj5WGVyWmWmdXPld{Bk\WyuII\pZYJqdGm2edMg MVyyNlQzPzF3NB?=
A375 MWPBdI9xfG:|aYOgRZN{[Xl? M3n6Z|ExKG6P NUTKWYpSOjRiaB?= MXfJcoR2[2W|IHPlcIwh[XCxcITvd4l{ MkLTNlMxPzlyOEO=
BLM NIfL[nFCeG:ydH;zbZMhSXO|YYm= NGjieGEyOCCwTR?= NIHJZogzPCCq NVP0VppzUW6mdXPld{Bk\WyuIHHwc5B1d3Orcx?= M33VclI{ODd7MEiz
A375 NFHYPYpCfXSxcHjh[5khSXO|YYm= NF3nXlIyOCCwTR?= NFS4UXAyOiCq NEjVS3ZKdmS3Y3XzJIZwem2jdHnvckBw\iCjdYTvdIhi\2:|b33ldy=> NWrkfI1VOjNyN{mwPFM>
BLM MmfjRZV1d3CqYXf5JGF{e2G7 NFXlUXEyOCCwTR?= M13kPVEzKGh? NGTZZWhKdmS3Y3XzJIZwem2jdHnvckBw\iCjdYTvdIhi\2:|b33ldy=> MUSyN|A4QTB6Mx?=
H1299 Mk[xRZBweHSxc3nzJGF{e2G7 MY[4NEBvVQ>? NVrlO2ZnOjRiaB?= NI\QNpBFVVOR M{\Db3NmdnOrdHn6[ZMhVlOFTFOgZ4VtdHNidH:gUXNENWSncnn2[YQhcUN7LXnu[JVk\WRiYYDvdJRwe2m| MWOyOVMzOzZ7Mx?=
Hut-78 MVjGeY5kfGmxbjDBd5NigQ>? NYDnOXcxOTByIH7N Ml70NlQhcA>? NHrucmpFVVOR M2DVPWRwf26{ZXf1cIF1\XNiVFfGMe6zOSCjbnSgTWwuOTBiZYjwdoV{e2mxbh?= MYiyOVY5OTN|NR?=
H9 M4GyUWZ2dmO2aX;uJGF{e2G7 NFfifWEyODBibl2= MlHoNlQhcA>? NF\OfXdFVVOR MXvEc5dvemWpdXzheIV{KFSJRj5OtlEh[W6mIFnMMVEyKGW6cILld5Nqd25? M{T1dlI2PjhzM{O1
HH M{OzRmZ2dmO2aX;uJGF{e2G7 NYT1bJVQOTByIH7N MVyyOEBp NV\te3NuTE2VTx?= M3\UeYRwf26{ZXf1cIF1\XNiVFfGMe6zOSCjbnSgTWwuOTJiZYjwdoV{e2mxbh?= NIrTWWIzPTZ6MUOzOS=>
Hut-78 MVfNbYdz[XSrb36gRZN{[Xl? NWX0d|hQOTByIH7N NYTL[GI4OjRiaB?= NXvDSZpETE2VTx?= NWrZVZdKWmWmdXPld{Bk\WyuIH3p[5JifGmxbjDifUA5OOLCk{mwKS=> NIHqRXAzPTZ6MUOzOS=>
HH MmjUUYloemG2aX;uJGF{e2G7 MXuxNFAhdk1? M2LyZ|I1KGh? NU\adlROTE2VTx?= MYTS[YR2[2W|IHPlcIwhdWmpcnH0bY9vKGK7IEiw5qCUQTFn NVrSdno4OjV4OEGzN|U>
U937 MXTGeY5kfGmxbjDBd5NigQ>? M2n1blExOCCwTR?= M{PJTFYhcA>? NGnpU4dKdmS3Y3XzJGlNNThiZYjwdoV{e2mxbjDpckBNWFNvc4TpcZVt[XSnZDDVPVM4KG2jY4LvdIhi\2W| M2XDUFI2PzlzNEe3
human PBMC NYPxUXZiTnWwY4Tpc44hSXO|YYm= M1ntNlExOCCwTR?= M2P5flI1KGh? MkPnTY5lfWOnczDJUE05KHKnbHXhd4U> M{LZOVI2PzlzNEe3
ES6 NYLOT2I6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXXJR|UxRTBwMECyNUBvVQ>? MWHTRW5ITVJ?
SK-UT-1 MmniS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MULJR|UxRTBwMU[zJI5O MYLTRW5ITVJ?
SH-4 MnnUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYfkV3czUUN3ME2wMlE4OyCwTR?= MVfTRW5ITVJ?
TE-9 M{L1Umdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVPQVZZOUUN3ME2wMlE5OiCwTR?= M2DaRXNCVkeHUh?=
A253 NGCwT|VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmToTWM2OD1yLkKwPEBvVQ>? NGe0TJdUSU6JRWK=
no-10 MoK2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYnJR|UxRTBwMkGgcm0> MlnUV2FPT0WU
MMAC-SF MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX3JR|UxRTBwMkG2JI5O MVXTRW5ITVJ?
A101D M3:0S2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXjJR|UxRTBwMkK1JI5O NUTPN5lGW0GQR1XS
NTERA-S-cl-D1 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4DPZ2lEPTB;MD6yOFMhdk1? MVfTRW5ITVJ?
8-MG-BA NYK5SoxyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1TYUmlEPTB;MD6yOUBvVQ>? M3[zW3NCVkeHUh?=
KNS-42 NHvXfoxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NG\WVmxKSzVyPUCuNlU5KG6P M2riXnNCVkeHUh?=
LXF-289 MmnQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYXJR|UxRTBwMk[5JI5O Mmf3V2FPT0WU
OVCAR-4 M4jwRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkDETWM2OD1yLkK4PUBvVQ>? M1q3dXNCVkeHUh?=
LOUCY NHX6dHVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWrtSnlNUUN3ME2wMlI6OyCwTR?= NIDOdWJUSU6JRWK=
BB65-RCC NXPh[VRST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn\JTWM2OD1yLkOwOEBvVQ>? NGfRbmdUSU6JRWK=
D-542MG NGDSVnpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MU\JR|UxRTBwM{K5JI5O Mk[zV2FPT0WU
ONS-76 M1nLVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWHJR|UxRTBwM{Ogcm0> M4Gyb3NCVkeHUh?=
BB30-HNC NWqwVYZtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2Tle2lEPTB;MD6zN|Uhdk1? NHXWOpZUSU6JRWK=
KS-1 Mm[1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYXJR|UxRTBwM{Sgcm0> M1fxOnNCVkeHUh?=
A388 M1nVSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmnoTWM2OD1yLkO1OkBvVQ>? Mke1V2FPT0WU
ES8 NUHYbIl4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEjBZlJKSzVyPUCuOEBvVQ>? MUXTRW5ITVJ?
MZ2-MEL NXHZOXI5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NInrNG5KSzVyPUCuOFA4KG6P MWLTRW5ITVJ?
HCC2998 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYfJR|UxRTBwNEGyJI5O MWHTRW5ITVJ?
D-247MG NYPzXo86T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEPSc|ZKSzVyPUCuOFE{KG6P NUS5XY9JW0GQR1XS
ACN NET3eINIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX;JR|ZjUUN3ME2wMlQyPyCwTR?= Mk\jV2FPT0WU
LB2518-MEL NHLaZW5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml3jTWM2OD1yLkSyOUBvVQ>? MofYV2FPT0WU
ES1 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVLJR|UxRTBwNEOgcm0> NEDj[VFUSU6JRWK=
HCE-T M3j6PGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnTyTWM2OD1yLkSzPUBvVQ>? NGSyZmxUSU6JRWK=
OS-RC-2 NYHoTo91T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmXXTWM2OD1yLkS0JI5O M2jFbnNCVkeHUh?=
MFH-ino NWHXUWJFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoLlTWM2OD1yLkS0N{BvVQ>? MVnTRW5ITVJ?
OCUB-M MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWToSY1FUUN3ME2wMlQ1PyCwTR?= M2fWXXNCVkeHUh?=
CP66-MEL NGPSOnBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1HKc2lEPTB;MD60O|Mhdk1? M{DmUXNCVkeHUh?=
LB771-HNC MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXXzOZdbUUN3ME2wMlQ4PCCwTR?= NUiyTXYxW0GQR1XS
DSH1 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MofVTWM2OD1yLkS4JI5O M1\MXHNCVkeHUh?=
HUTU-80 NVzzWWhHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlS5TWM2OD1yLkWzN{BvVQ>? M1PMOHNCVkeHUh?=
CESS NFXxc4JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2P3UGlEPTB;MD61N|ghdk1? M2TJfnNCVkeHUh?=
NCI-H747 NHTkT2NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV7JR|UxRTBwNUO5JI5O Ml\RV2FPT0WU
HT-144 NWP6eIljT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGWwb|FKSzVyPUCuOVc3KG6P NYCyUXl[W0GQR1XS
COLO-829 NHPMbo5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUTJR|UxRTBwNkG0JI5O M2DJbnNCVkeHUh?=
A4-Fuk MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4KxOWlEPTB;MD62NlMhdk1? MYPTRW5ITVJ?
GI-ME-N NEfnOIFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX;JR|UxRTBwNkO0JI5O MUHTRW5ITVJ?
LB831-BLC M2TUbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUjJR|UxRTBwNkSxJI5O MXjTRW5ITVJ?
HOP-62 NYrnS41OT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVLJR|UxRTBwNkS3JI5O NFfOeI5USU6JRWK=
BB49-HNC NHzVSVhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3\pRWlEPTB;MD62OVIhdk1? MYLTRW5ITVJ?
D-336MG MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGHWb2tKSzVyPUCuOlU4KG6P NUT4XnBEW0GQR1XS
TK10 NHnzRmhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVXJR|UxRTBwNke5JI5O MX;TRW5ITVJ?
Ramos-2G6-4C10 M2e4WWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4K5XWlEPTB;MD62PVMhdk1? MWDTRW5ITVJ?
LB373-MEL-D NX;oRlNMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml3nTWM2OD1yLkegcm0> NXOxfohYW0GQR1XS
SF126 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{T6XGlEPTB;MD63NFEhdk1? M3HQR3NCVkeHUh?=
UACC-257 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWKxTW1uUUN3ME2wMlcyKG6P MWPTRW5ITVJ?
KINGS-1 NYDvO2plT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUi3fpYzUUN3ME2wMlczOiCwTR?= MofDV2FPT0WU
LS-513 M{\JTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV[3fG1yUUN3ME2wMlc{QSCwTR?= NU\MWlYzW0GQR1XS
GI-1 NXXqRZF1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXnNTXRNUUN3ME2wMlc3PCCwTR?= MnWyV2FPT0WU
ES7 MoLzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoLvTWM2OD1yLke2OkBvVQ>? NYr3RpRPW0GQR1XS
LB2241-RCC NIS0Z4pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1LHWmlEPTB;MD64NFQhdk1? MWnTRW5ITVJ?
D-263MG NXPOe4tqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXPJR|UxRTBwOEC3JI5O MWPTRW5ITVJ?
SW684 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MknKTWM2OD1yLkiyNUBvVQ>? NGntVFlUSU6JRWK=
ML-2 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2TxPGlEPTB;MD64NlEhdk1? NF35dlFUSU6JRWK=
SK-LMS-1 MkHQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml3kTWM2OD1yLki1OEBvVQ>? NXmyeIZpW0GQR1XS
TE-5 NHXlR2xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWfJR|UxRTBwOE[1JI5O M{XWfnNCVkeHUh?=
QIMR-WIL M3rxSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4PkWmlEPTB;MD64PFkhdk1? MUHTRW5ITVJ?
NCI-H1355 NFLSfmFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUH5PFVLUUN3ME2wMlg6PSCwTR?= M4i1[HNCVkeHUh?=
SNB75 NXrkeGtyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4D4N2lEPTB;MD65NVIhdk1? NWTuZpZzW0GQR1XS
RXF393 MkDOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn\LTWM2OD1yLkmxOEBvVQ>? M{HmNHNCVkeHUh?=
IST-MEL1 MnznS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkDjTWM2OD1yLkmxO{BvVQ>? NVjsTYFSW0GQR1XS
SF268 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFHC[YFKSzVyPUCuPVI{KG6P MlzNV2FPT0WU
KALS-1 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4fXVWlEPTB;MD65NlUhdk1? NWnJSJU3W0GQR1XS
HC-1 MoPzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3vkdmlEPTB;MD65O|Uhdk1? NF73NotUSU6JRWK=
SW872 NWPPS4c3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4L5cGlEPTB;MD65PVYhdk1? NEHZVINUSU6JRWK=
PSN1 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXLkfJVOUUN3ME2xMlAyKG6P MnvFV2FPT0WU
TE-1 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH7XSGZKSzVyPUGuNFMhdk1? NFe1WXRUSU6JRWK=
TE-10 Mn7vS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVrJR|UxRTFwMEOgcm0> M4PzU3NCVkeHUh?=
RKO M3izV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVvJR|UxRTFwME[gcm0> NUO2Roh5W0GQR1XS
LC-2-ad Mn7GS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkC0TWM2OD1zLkC4JI5O NH7tdWRUSU6JRWK=
SK-MM-2 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVnJR|UxRTFwMEmgcm0> MkTRV2FPT0WU
VA-ES-BJ NEDQW5lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVHRcGk2UUN3ME2xMlA6KG6P MmXKV2FPT0WU
MZ7-mel NWLoOlhmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXOxSWZJUUN3ME2xMlA6KG6P MnPYV2FPT0WU
D-392MG MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnvqTWM2OD1zLkGgcm0> M2WxV3NCVkeHUh?=
CCRF-CEM MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEj6Z3dKSzVyPUGuNVMhdk1? M4PuTXNCVkeHUh?=
EM-2 M{X3bGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlzGTWM2OD1zLkG2JI5O NGjnOJFUSU6JRWK=
HAL-01 Ml\PS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF65WmdKSzVyPUGuNVghdk1? NVO5c211W0GQR1XS
TE-8 M4Pq[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoOwTWM2OD1zLkG5JI5O NXOxSYt2W0GQR1XS
NCI-H1882 MkTiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUjmWWlqUUN3ME2xMlIhdk1? MmTrV2FPT0WU
Daudi NXfzXWZbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkXVTWM2OD1zLkKyJI5O MlzQV2FPT0WU
BL-41 MorVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1\mSWlEPTB;MT6yOUBvVQ>? M{nFb3NCVkeHUh?=
SR NGjsb4RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2H5W2lEPTB;MT6yOUBvVQ>? NXjVSYFSW0GQR1XS
KM12 M3PlTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV7oO5pHUUN3ME2xMlI4KG6P NHv0flZUSU6JRWK=
K5 M4DucGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{fxd2lEPTB;MT6yPEBvVQ>? NGrGXotUSU6JRWK=
A3-KAW NUHHTlN5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnnMTWM2OD1zLkK4JI5O Mn7kV2FPT0WU
CMK M{DTdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVrpdpZMUUN3ME2xMlI6KG6P NWD0[mxZW0GQR1XS
Calu-6 MmLpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWHGNXN7UUN3ME2xMlI6KG6P NVLFeIhLW0GQR1XS
IST-SL2 M3Hzb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWDWUHMzUUN3ME2xMlMyKG6P NV3yfJJyW0GQR1XS
OPM-2 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlPuTWM2OD1zLkOzJI5O NWjKSZpEW0GQR1XS
DU-4475 NIj2UVNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkXLTWM2OD1zLkO2JI5O NYrCb|NNW0GQR1XS
ECC12 NWq1UZhYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1nKXWlEPTB;MT6zO{BvVQ>? NFHSTZdUSU6JRWK=
L-540 Mn\3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUXJR|UxRTFwM{egcm0> MV\TRW5ITVJ?
CAS-1 NWLSSnBuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkXJTWM2OD1zLkO3JI5O MkPaV2FPT0WU
PF-382 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkTmTWM2OD1zLkS3JI5O MoPHV2FPT0WU
LS-411N NEPKe5FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIHmc49KSzVyPUGuOVMhdk1? NIe1fWhUSU6JRWK=
NCI-H69 NYLIZppYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3:3OmlEPTB;MT61OEBvVQ>? NID3V5NUSU6JRWK=
NB12 NX7Kd4VmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVrnfWZMUUN3ME2xMlU3KG6P NULQRpEyW0GQR1XS
HEL NGnJSW5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGjvNHJKSzVyPUGuOlEhdk1? MWDTRW5ITVJ?
GCIY MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2DUc2lEPTB;MT62NkBvVQ>? NV25R3V3W0GQR1XS
EHEB MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGriTJBKSzVyPUGuOlchdk1? M4i4W3NCVkeHUh?=
TGBC1TKB MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFqyXldKSzVyPUGuO|Ehdk1? M{DtN3NCVkeHUh?=
KURAMOCHI MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mo\zTWM2OD1zLkeyJI5O MkLjV2FPT0WU
U-266 NXPuVVMzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGTE[IVKSzVyPUGuO|Yhdk1? MonWV2FPT0WU
LC4-1 MlP5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnzrTWM2OD1zLke5JI5O MlrpV2FPT0WU
NCI-H2126 Mn2xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUDJR|UxRTFwODDuUS=> MVPTRW5ITVJ?
NCI-H1092 M1fsW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1e1[GlEPTB;MT64JI5O MVvTRW5ITVJ?
GB-1 NGjqZodIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHPjellKSzVyPUGuPFEhdk1? MmiwV2FPT0WU
MV-4-11 Mnu1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoiwTWM2OD1zLkiyJI5O MYXTRW5ITVJ?
Becker MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYnkVHo2UUN3ME2xMlg{KG6P NF7lbpFUSU6JRWK=
MPP-89 M4S0emdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml7yTWM2OD1zLki5JI5O M4PXNHNCVkeHUh?=
BE-13 NYjYOpBnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkO0TWM2OD1zLkmzJI5O MkC0V2FPT0WU
697 MlfKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlTuTWM2OD1zLkm5JI5O MYLTRW5ITVJ?
NKM-1 MoDNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnfrTWM2OD1{IH7N MWnTRW5ITVJ?
NB13 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2Lv[2lEPTB;MjDuUS=> NF3nZ3BUSU6JRWK=
LS-123 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2HQPGlEPTB;Mj6wNkBvVQ>? MX\TRW5ITVJ?
NB17 M4rPe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGTzUWpKSzVyPUKuNFQhdk1? M{XBN3NCVkeHUh?=
LAN-6 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX7xWGtQUUN3ME2yMlA2KG6P NUHlT25RW0GQR1XS
EW-24 NWjid21XT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkGwTWM2OD1{LkC4JI5O MWfTRW5ITVJ?
NOS-1 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGOwdnpKSzVyPUKuNVEhdk1? NV;UZVdUW0GQR1XS
BL-70 NGfkRmlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3ziTGlEPTB;Mj6xNkBvVQ>? MXrTRW5ITVJ?
GT3TKB M3HtNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWrQZmg4UUN3ME2yMlEzKG6P MVjTRW5ITVJ?
HH NWLP[GN{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoLqTWM2OD1{LkGzJI5O Mn31V2FPT0WU
KE-37 NEHGWYZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2LEXmlEPTB;Mj6xN{BvVQ>? NWjj[2E4W0GQR1XS
MOLT-4 M3;jZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{\x[mlEPTB;Mj6xN{BvVQ>? MYfTRW5ITVJ?
EKVX NVT0XHBLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXLRNIZLUUN3ME2yMlE1KG6P MkGxV2FPT0WU
KGN NVnTTItyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV7SRYpQUUN3ME2yMlE2KG6P M4nBTnNCVkeHUh?=
ES4 MlLBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYfJR|UxRTJwMU[gcm0> MmXiV2FPT0WU
SJSA-1 NVjMfnA3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGH3SGZKSzVyPUKuNlEhdk1? NUi0[IhZW0GQR1XS
KMOE-2 NUDVUHpDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnnrTWM2OD1{LkKzJI5O M{LoN3NCVkeHUh?=
NB5 MmTBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlfCTWM2OD1{LkK3JI5O MoD3V2FPT0WU
BC-1 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYfJR|UxRTJwM{Ggcm0> NWrsVJFXW0GQR1XS
NB10 MoD6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUTXR2VJUUN3ME2yMlMzKG6P M3PMOXNCVkeHUh?=
RPMI-8226 MlL4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlL6TWM2OD1{LkO1JI5O NFnp[3RUSU6JRWK=
SCC-3 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFfwcm5KSzVyPUKuN|chdk1? NGHHe3NUSU6JRWK=
ARH-77 MlzTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUHkNlFKUUN3ME2yMlM5KG6P M4rGO3NCVkeHUh?=
NCI-H748 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUjJR|UxRTJwM{mgcm0> NGHmR4dUSU6JRWK=
KU812 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIXXU|FKSzVyPUKuOFIhdk1? MknCV2FPT0WU
NCI-H64 NXPDO|hRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXricY86UUN3ME2yMlQ1KG6P M3XMd3NCVkeHUh?=
NB69 M3\BVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWnZWJltUUN3ME2yMlQ3KG6P NULyUpZ5W0GQR1XS
KNS-81-FD MkDnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXu5eZUyUUN3ME2yMlQ5KG6P M120cnNCVkeHUh?=
LB1047-RCC Ml3DS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MY\JR|UxRTJwNUegcm0> M3PCXXNCVkeHUh?=
EB-3 NX;lepBET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIDp[W1KSzVyPUKuOlYhdk1? M1fteXNCVkeHUh?=
Mo-T M2nkTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmfsTWM2OD1{Lke0JI5O M2njeXNCVkeHUh?=
EW-16 NVzGV2tmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmT0TWM2OD1{Lke1JI5O M{LPUHNCVkeHUh?=
CTV-1 MnPQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkjITWM2OD1{Lkigcm0> M4GwO3NCVkeHUh?=
ETK-1 MlvvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYrJR|UxRTJwOESgcm0> Mn7GV2FPT0WU
C2BBe1 NWW4[VFVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{jOXGlEPTB;Mj64PUBvVQ>? NI\l[5VUSU6JRWK=
MOLT-16 MnzxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1m3ZmlEPTB;Mj64PUBvVQ>? M3;s[HNCVkeHUh?=
SW954 NHzrSVBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkPVTWM2OD1{Lkmgcm0> NGTmRldUSU6JRWK=
HT M3npdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV\JR|UxRTNwMEKgcm0> MmH0V2FPT0WU
KARPAS-299 NHPpeVZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUWzPJVTUUN3ME2zMlA3KG6P M3iyZ3NCVkeHUh?=
MONO-MAC-6 M2PGN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3\4RmlEPTB;Mz6xJI5O MUjTRW5ITVJ?
CGTH-W-1 M3;NSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFvwbZBKSzVyPUOuNUBvVQ>? MULTRW5ITVJ?
SK-PN-DW NIGxW5RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3;OSWlEPTB;Mz6xOEBvVQ>? NXPTZVZFW0GQR1XS
CW-2 NILoTmRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkHWTWM2OD1|LkKxJI5O M{e5OnNCVkeHUh?=
SK-N-DZ MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2nLdGlEPTB;Mz6yOkBvVQ>? M3jWV3NCVkeHUh?=
NEC8 NF;rWJRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWXJR|UxRTNwM{Wgcm0> MnLSV2FPT0WU
LB996-RCC NH70OHhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1O2e2lEPTB;Mz60JI5O M4TxT3NCVkeHUh?=
DB MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEewPWVKSzVyPUOuOFEhdk1? NHrXcoZUSU6JRWK=
TE-15 M1jzRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX;JR|UxRTNwNEOgcm0> NW\I[ohQW0GQR1XS
COR-L88 NWnyN5FyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NG\ES|FKSzVyPUOuOFchdk1? Mn71V2FPT0WU
LAMA-84 NX22cHF2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoLFTWM2OD1|LkS5JI5O M3TROXNCVkeHUh?=
MEG-01 NYjY[Jh6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXfsRlNiUUN3ME2zMlQ6KG6P MX7TRW5ITVJ?
LOXIMVI MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXXqbGVxUUN3ME2zMlUhdk1? NIK1NohUSU6JRWK=
RPMI-8402 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWDRRpBpUUN3ME2zMlUhdk1? M1q3cXNCVkeHUh?=
KARPAS-45 NV\2ZYpmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M33KWGlEPTB;Mz61OEBvVQ>? MlvSV2FPT0WU
HCC1187 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGLPUZpKSzVyPUOuOVQhdk1? NELldFNUSU6JRWK=
MZ1-PC M4D6[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUjPSGU3UUN3ME2zMlU1KG6P MmPvV2FPT0WU
no-11 M1Ph[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX;JR|UxRTNwNUWgcm0> NEnwcnNUSU6JRWK=
EVSA-T NEnmfFBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4\xXGlEPTB;Mz62JI5O NXnaOI44W0GQR1XS
DJM-1 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYHJR|UxRTNwNkOgcm0> NXvsfYFbW0GQR1XS
COLO-684 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVXp[m02UUN3ME2zMlY3KG6P MmH3V2FPT0WU
NMC-G1 NEPV[nNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoTiTWM2OD1|Lk[4JI5O NGjRWGlUSU6JRWK=
LC-1F MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV\JR|UxRTNwN{Sgcm0> NIX4e|hUSU6JRWK=
RL95-2 NUHkeXBkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{P1NWlEPTB;Mz63PUBvVQ>? MV3TRW5ITVJ?
COLO-320-HSR MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3v1XmlEPTB;Mz65NkBvVQ>? MYXTRW5ITVJ?
RCC10RGB MoDlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWrX[41XUUN3ME2zMlk{KG6P NGfqS|hUSU6JRWK=
HD-MY-Z NInEPJZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1W2e2lEPTB;Mz65N{BvVQ>? NVHQVZlSW0GQR1XS
NCI-H2141 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVzJR|UxRTRwMEWgcm0> M1fsNXNCVkeHUh?=
K-562 M4DiTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYHJR|UxRTRwMUKgcm0> MYrTRW5ITVJ?
NCI-H1648 NWjmS4RlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHHpe4RKSzVyPUSuNVMhdk1? NGrhV3ZUSU6JRWK=
OMC-1 MnrIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3vlS2lEPTB;ND6xPEBvVQ>? NWXkSotTW0GQR1XS
LB647-SCLC NGnOW|hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1znWGlEPTB;ND6yNkBvVQ>? MYLTRW5ITVJ?
TE-12 NYC0PJM4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2m5TmlEPTB;ND6yOUBvVQ>? MWPTRW5ITVJ?
NOMO-1 M3e4WWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVzsTpdrUUN3ME20MlM{KG6P NHj0OXhUSU6JRWK=
Raji NU\PXlFiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV3JR|UxRTRwNE[gcm0> NH\Zdo1USU6JRWK=
NALM-6 NYqyNmlNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHrxN3hKSzVyPUSuOFkhdk1? NG\MWmlUSU6JRWK=
HL-60 NF23S3FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWn4c2l4UUN3ME20MlY4KG6P NVvnTVlmW0GQR1XS
IST-SL1 Mlj2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{nP[WlEPTB;ND62PEBvVQ>? M4fUbnNCVkeHUh?=
MHH-PREB-1 NHP6T5hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3f4RWlEPTB;ND64OkBvVQ>? NHLXeFFUSU6JRWK=
MHH-NB-11 MlHYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlzpTWM2OD12LkmxJI5O MkG5V2FPT0WU
JiyoyeP-2003 NXz5SppFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml;DTWM2OD13IH7N NFrxdmVUSU6JRWK=
SBC-1 NVzmUZBET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWjJR|UxRTVwMEGgcm0> NH\1[4dUSU6JRWK=
CHP-126 NWmzZXJrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUL0bm5nUUN3ME21MlA3KG6P MWrTRW5ITVJ?
LU-139 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYHJR|UxRTVwMUOgcm0> MXTTRW5ITVJ?
NCI-SNU-5 NILpZoxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NU\1V25YUUN3ME21MlE4KG6P Mo\4V2FPT0WU
SW962 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2rHc2lEPTB;NT6yNUBvVQ>? MorzV2FPT0WU
EW-1 NUDzdFA1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYPJR|UxRTVwM{Ggcm0> NYrlNIcxW0GQR1XS
NCI-H1417 Mny0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV\JR|UxRTVwNUGgcm0> M3vnTHNCVkeHUh?=
LU-65 NYriVodsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUnBO4VVUUN3ME21Mlg1KG6P NEnyN4hUSU6JRWK=
D-502MG MoDKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWq3XIU1UUN3ME22MlM4KG6P MW\TRW5ITVJ?
BC-3 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn\DTWM2OD14Lk[xJI5O MYHTRW5ITVJ?
GDM-1 NUK4NGJTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF3WfmVKSzVyPU[uO|chdk1? MlXQV2FPT0WU
NCI-H2196 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXTJR|UxRTZwODDuUS=> M{[0cXNCVkeHUh?=
NB1 NIXueJdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWLJR|UxRTZwOEigcm0> NYLL[3BWW0GQR1XS
NCI-H345 NUX2RXdjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX\TWHZpUUN3ME23MlIhdk1? NWT6PHptW0GQR1XS
SU-DHL-1 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX;weIFKUUN3ME23MlI1KG6P NFLreY9USU6JRWK=
JVM-2 M1LPVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4\5bGlEPTB;Nz6yPEBvVQ>? NWXiRpMyW0GQR1XS
LU-134-A NVe0dXFrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2nVcWlEPTB;Nz6zPUBvVQ>? NUnqc4V2W0GQR1XS
NCI-H1694 NUSyNIVST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MknnTWM2OD15LkW4JI5O M2XP[nNCVkeHUh?=
NCI-SNU-16 NHfSNnZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Moq1TWM2OD15Lk[1JI5O MofDV2FPT0WU
L-363 M{LEeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MULJR|UxRTdwNzDuUS=> MmW3V2FPT0WU
KG-1 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnjZTWM2OD15Lkm0JI5O NUS0dIxrW0GQR1XS
MN-60 M3;WTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkC3TWM2OD16LkG0JI5O MmnmV2FPT0WU
NB6 M2PHeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFWzdoVKSzVyPUiuOFghdk1? M4rHOXNCVkeHUh?=
MLMA NHjzc4VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnTJTWM2OD16Lki1JI5O NHLPTI5USU6JRWK=
ATN-1 NVPjdZdbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUPJR|UxRThwOEmgcm0> NYTIfo5rW0GQR1XS
SK-NEP-1 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{PheGlEPTB;OT6wNUBvVQ>? NYfUfGc5W0GQR1XS
DMS-114 MmHvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXL4NoVUUUN3ME25MlYzKG6P M2TvVnNCVkeHUh?=
CTB-1 MnjSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWezclFrUUN3ME25MlY4KG6P MoiwV2FPT0WU
NCI-H2081 NYTXU3JFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFTYUZpKSzVyPUGwMlA6KG6P M2fVfnNCVkeHUh?=
ES5 MnfqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX7E[mdbUUN3ME2xNE4{QCCwTR?= M3TYOHNCVkeHUh?=
HCC1599 M4DtcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUHJR|UxRTFzLkmxJI5O MVLTRW5ITVJ?
NCI-H23 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYfzR3JkUUN3ME2xNk4yOiCwTR?= MonjV2FPT0WU
NCI-H1581 M{[zZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXTJR|UxRTF{LkK4JI5O Mo\hV2FPT0WU
JVM-3 Mnr2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVfHeG1wUUN3ME2xNk46QSCwTR?= NVyzNWJkW0GQR1XS
NCI-SNU-1 M{HqUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NELQTm5KSzVyPUGzMlE6KG6P MYnTRW5ITVJ?
NB7 NIPNXXFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYC0TYo2UUN3ME2xOU46OiCwTR?= MVfTRW5ITVJ?
JAR MnTwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1K4VGlEPTB;MU[uNVMhdk1? MVXTRW5ITVJ?
TGW MnzsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX7JR|UxRTF4LkS4JI5O NYSwUY9zW0GQR1XS
U-87-MG M{Xoe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUDJR|UxRTF4Lke2JI5O NFL6S5pUSU6JRWK=
NCI-H1436 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MULJR|UxRTF5LkCxJI5O NEPOPGxUSU6JRWK=
GOTO MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NE\aTJVKSzVyPUG3MlA3KG6P NFrocndUSU6JRWK=
COLO-800 NV7TR4ZpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mmr4TWM2OD1zNz62OEBvVQ>? MV;TRW5ITVJ?
MFM-223 M1;qOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHvXbHNKSzVyPUG3MlkyKG6P MkLKV2FPT0WU
EW-18 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYfJR|UxRTF5Lkm2JI5O MXPTRW5ITVJ?
NB14 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH3xUo5KSzVyPUG3Mlk5KG6P NEi3OoJUSU6JRWK=
EB2 M2W5SWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mme4TWM2OD1zOD6wPEBvVQ>? NYP4fIE3W0GQR1XS
EoL-1- M1fSXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHnxfpFKSzVyPUG4MlMyKG6P M{i5eXNCVkeHUh?=
NCCIT NGnBVmlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHHzSo9KSzVyPUG4MlM3KG6P Mnm1V2FPT0WU
DG-75 NGKwVoJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkDzTWM2OD1zOD62NUBvVQ>? NIDPeZZUSU6JRWK=
HCC2218 NX7hfHZ[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2r2eWlEPTB;MUmuOUBvVQ>? M4D3dXNCVkeHUh?=
TE-6 M3zzeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVvJR|UxRTJyLkC4JI5O M{XqPHNCVkeHUh?=
SF539 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWLJR|UxRTJyLk[3JI5O MYHTRW5ITVJ?
NCI-H446 M3vvR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXm1ZXhnUUN3ME2yNU4yQCCwTR?= MoLjV2FPT0WU
IST-MES1 NHvidmFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmnTTWM2OD1{Mj63O{BvVQ>? MnXpV2FPT0WU
NCI-H82 M{Duemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoDXTWM2OD1{Mz6wNkBvVQ>? NX3xPG9TW0GQR1XS
HCC2157 NWDofnd2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYT6NpVuUUN3ME2yN{4yOyCwTR?= NFTWeFFUSU6JRWK=
EW-12 M17vbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWXhXHRkUUN3ME2yN{4yPyCwTR?= NIq5UVhUSU6JRWK=
SIMA MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWrJR|UxRTJ|LkO4JI5O MUjTRW5ITVJ?
DOHH-2 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnXoTWM2OD1{Mz60OUBvVQ>? MknwV2FPT0WU
IM-9 M4TDVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIjPUWZKSzVyPUKzMlU1KG6P MWXTRW5ITVJ?
EC-GI-10 NHnZXWZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoHiTWM2OD1{ND6yN{BvVQ>? MY\TRW5ITVJ?
HDLM-2 NYPTSnN5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYHXeIdPUUN3ME2yOE42PCCwTR?= NVP1U4J2W0GQR1XS
LS-1034 M2XidWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVvWTHlzUUN3ME2yOU44PSCwTR?= NVPtW25xW0GQR1XS
REH MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mm\nTWM2OD1{Nj60NUBvVQ>? NFyySJpUSU6JRWK=
LU-165 M2TCUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnriTWM2OD1{Nj63NkBvVQ>? NXewTZBxW0GQR1XS
NH-12 Mof5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYPHUYozUUN3ME2yO{43PyCwTR?= NWHIdWVzW0GQR1XS
WSU-NHL MnntS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NITYW5FKSzVyPUK4MlM6KG6P MlXmV2FPT0WU
ECC4 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWn5WFlyUUN3ME2yPE44QSCwTR?= MXjTRW5ITVJ?
OCI-AML2 M13YXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEfJVVZKSzVyPUK5MlY6KG6P MUDTRW5ITVJ?
EW-3 NWTzOWs2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFjYdGdKSzVyPUOwMlU6KG6P NH\MV5dUSU6JRWK=
NCI-H526 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnHHTWM2OD1|Mj61OEBvVQ>? MXjTRW5ITVJ?
NCI-H719 Mmj3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUf6NoViUUN3ME2zOE4{OSCwTR?= M3jXXHNCVkeHUh?=
KARPAS-422 MoDDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MULJR|UxRTN3LkC0JI5O NXPXNnE5W0GQR1XS
SK-MEL-1 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHXLS4VKSzVyPUO1MlE4KG6P MlPOV2FPT0WU
ES3 NYThOYFHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXHGUnM4UUN3ME2zOU4yQSCwTR?= NHvqc5VUSU6JRWK=
UACC-812 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnK1TWM2OD1|NT60OEBvVQ>? MVrTRW5ITVJ?
C8166 NVrReHk1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmXYTWM2OD1|NT63JI5O Mn\DV2FPT0WU
MDA-MB-134-VI NHi3TotIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF;5b41KSzVyPUO1Mlg4KG6P NXPpXG9jW0GQR1XS
D-283MED NVXCdlRQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlfzTWM2OD1|Nz63PUBvVQ>? MYHTRW5ITVJ?
SHP-77 M4DFZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX;JR|UxRTN6LkCzJI5O NYm1SYdPW0GQR1XS
NCI-H2227 NVznWJRST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIPnUI1KSzVyPUSwMlQ6KG6P MVHTRW5ITVJ?
SKM-1 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXrWU3NzUUN3ME20Nk43OyCwTR?= MYTTRW5ITVJ?
L-428 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX7wbpNGUUN3ME20N{45PiCwTR?= MoKyV2FPT0WU
RPMI-6666 M1i3d2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXLJNJFqUUN3ME20OU45QSCwTR?= MnTpV2FPT0WU
NCI-H716 MoDMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVTJR|UxRTR6LkixJI5O NHrjZXRUSU6JRWK=
DMS-79 M{LTPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHfkVpVKSzVyPUWwMlcyKG6P NXzUVJI5W0GQR1XS
RS4-11 NYfGN5kxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1XCdGlEPTB;NUCuPFghdk1? NVnFeoNkW0GQR1XS
NCI-H720 NXfDU4JbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkHKTWM2OD13MT6xNUBvVQ>? MnvLV2FPT0WU
MC-CAR NEn0VWhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1W5UWlEPTB;NUGuOVIhdk1? NI\hXFZUSU6JRWK=
TALL-1 NEjxPGhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4juVmlEPTB;NUOuPVEhdk1? NYe0UFQ2W0GQR1XS
NCI-N87 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1zRZWlEPTB;NUSuNVghdk1? M1HNSHNCVkeHUh?=
P30-OHK MmToS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXfJR|UxRTV2Lk[xJI5O NG[ycZlUSU6JRWK=
LP-1 NV32[YFyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUjhWVdDUUN3ME22NU4zQCCwTR?= M2ezZnNCVkeHUh?=
YT Mke1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NG[4WJlKSzVyPU[xMlghdk1? MY\TRW5ITVJ?
MRK-nu-1 MmHyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFjVcW9KSzVyPU[xMlgzKG6P MoToV2FPT0WU
BT-474 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml;BTWM2OD14NTDuUS=> MUHTRW5ITVJ?
NCI-H322M M1zyUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3PKZmlEPTB;Nk[uNVEhdk1? NUGzS3ZNW0GQR1XS
NCI-H128 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHvXXnRKSzVyPUe0Mlc4KG6P M2HKfnNCVkeHUh?=
KMS-12-PE NITFTGNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWf4bGU{UUN3ME23Ok4zPCCwTR?= M2LPNXNCVkeHUh?=
KP-N-YS NHHZSXNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoD2TWM2OD15Nj63OEBvVQ>? M{TjenNCVkeHUh?=
ALL-PO MkLxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3Xqe2lEPTB;N{euOlYhdk1? MmPoV2FPT0WU
EW-13 NYjjW2M1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnqzTWM2OD15Nz63OkBvVQ>? NIHTUplUSU6JRWK=
EW-11 NIS1PYhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF;uRYhKSzVyPUe4MlUzKG6P MWPTRW5ITVJ?
SK-N-FI MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGDB[3BKSzVyPUiwMlIhdk1? MnzPV2FPT0WU
CAL-148 M3PQV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWHUfVVWUUN3ME24NU45PCCwTR?= MWnTRW5ITVJ?
RL M2X0U2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{jkcWlEPTB;OE[uNFkhdk1? NIP0eJlUSU6JRWK=
AM-38 NVTCTnRQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1;G[2lEPTB;OEiuNFghdk1? NYLxWlJCW0GQR1XS
RH-1 M2\OfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mne1TWM2OD17OT64OUBvVQ>? NHTLeXpUSU6JRWK=
NCI-H1770 MmH1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NULI[3FiUUN3ME2xNFIvPDlibl2= Mn;mV2FPT0WU
SIG-M5 M4XCdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXjJR|UxRTFyNT6wOkBvVQ>? M4[yXHNCVkeHUh?=
GR-ST NXz1eVhMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlnETWM2OD1zMUOuN|Qhdk1? NX7nSHV5W0GQR1XS
ST486 M4rS[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3:3bWlEPTB;MUG0MlA3KG6P NHjHbIZUSU6JRWK=
NCI-H1650 MkLDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHmzU2lKSzVyPUGxOU4zQSCwTR?= NUG2VXJKW0GQR1XS
MHH-CALL-2 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NG\NZoZKSzVyPUGxOU44KG6P M3TwU3NCVkeHUh?=
BV-173 M1ewemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH\xSpNKSzVyPUGyNk44OSCwTR?= NIG0d5JUSU6JRWK=
MC116 MnfWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoK0TWM2OD1zNEiuPFUhdk1? M4jRPXNCVkeHUh?=
NCI-H524 NYPnW4hDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2PTU2lEPTB;MUW5MlEhdk1? NV24WVBFW0GQR1XS
SCLC-21H M3fIdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF20epNKSzVyPUG1PU41OSCwTR?= NVPKfVl2W0GQR1XS
NCI-H1304 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFfNbmhKSzVyPUG2PU4zOSCwTR?= NWrNeI94W0GQR1XS
NCI-H510A MkXsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFn2O5VKSzVyPUG4OU4{PyCwTR?= NFHqR|BUSU6JRWK=
NCI-H209 M3OxXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2\lemlEPTB;MUm2MlUzKG6P Mn2xV2FPT0WU
KM-H2 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2K4TWlEPTB;MUm3MlA2KG6P NFHmVYhUSU6JRWK=
NCI-H1395 MnHvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUfNfWJQUUN3ME2yNVAvOTNibl2= NFLZcWhUSU6JRWK=
NCI-H1155 MlP6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4PTXWlEPTB;MkOwMlMzKG6P MYLTRW5ITVJ?
COR-L279 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXvJR|UxRTJ3Mj6xO{BvVQ>? M123N3NCVkeHUh?=
NCI-H1299 NFfXcWRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVHJR|UxRTJ4MT63NUBvVQ>? MkPVV2FPT0WU
EW-22 NWXhVpdbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWfR[GtZUUN3ME2yOlMvPzVibl2= NFOyXFRUSU6JRWK=
SK-MEL-2 M4DKc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M361OmlEPTB;MkixMlkhdk1? NGrLV3dUSU6JRWK=
KASUMI-1 NEf6dFJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHL3[2pKSzVyPUK4N{4xPSCwTR?= M4LKPHNCVkeHUh?=
NCI-H187 NXvsfGZpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWLxcnN3UUN3ME2yPFcvODhibl2= NEXFOVFUSU6JRWK=
NCI-H2171 M1\JR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NETuZWlKSzVyPUK4PE46OiCwTR?= NFO4OZBUSU6JRWK=
LNCaP-Clone-FGC NVjvT4doT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlzHTWM2OD1{OUWuNlYhdk1? M4OzTnNCVkeHUh?=
NCI-H1522 MmL5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUTCZWVoUUN3ME2zNFcvODVibl2= MV;TRW5ITVJ?
SCH NG\s[HJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlnrTWM2OD1|MkKuNlIhdk1? M{XWeXNCVkeHUh?=
THP-1 M4HiT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXLJR|UxRTN{Mj62JI5O MoPWV2FPT0WU
SNU-C1 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVPJR|UxRTN4Mj6wPUBvVQ>? MnKwV2FPT0WU
CA46 Mme2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVrWfYVEUUN3ME2zO|MvPjNibl2= MlvZV2FPT0WU
NCI-H1963 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mkm1TWM2OD1|OE[uNVkhdk1? MkXkV2FPT0WU
DEL NGLOTI5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlzVTWM2OD1|OUGuNlchdk1? Ml7OV2FPT0WU
TUR MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmnFTWM2OD1|OU[uOlEhdk1? M{npZXNCVkeHUh?=
NCI-H226 NV3vOJVwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2TsZmlEPTB;NECzMlI{KG6P NFjKTYdUSU6JRWK=
COLO-668 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEjRe3pKSzVyPUSwN{42PyCwTR?= MVzTRW5ITVJ?
CPC-N M4X4eWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIjPfmpKSzVyPUSwN{44PyCwTR?= MVLTRW5ITVJ?
NCI-H889 MknBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHjyb3FKSzVyPUS2NU46OiCwTR?= NVXXSVZ[W0GQR1XS
J-RT3-T3-5 NFXsZZhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnjPTWM2OD13M{KuOVchdk1? M2\MNXNCVkeHUh?=
MSTO-211H M4TvbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVHqfZpJUUN3ME21O|QvOjZibl2= M4jNXHNCVkeHUh?=
SCC-15 Mn;LS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWjsOmtWUUN3ME22OlcvPDdibl2= MXrTRW5ITVJ?
SUP-T1 NFq5fZVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXPJR|UxRTZ6Nj6wOEBvVQ>? NYH3cHFWW0GQR1XS
DMS-153 M1foRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MluzTWM2OD15NE[uPFMhdk1? MkHzV2FPT0WU
MS-1 Mn\BS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVHJR|UxRTd3OT60NkBvVQ>? MWrTRW5ITVJ?
TC-YIK M{PjT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn3oTWM2OD15OEGuNFEhdk1? NUfXXHNOW0GQR1XS
RPMI-8866 M{nre2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4\RVmlEPTB;MUCwOk4zQCEQvF2= NIDvVJRUSU6JRWK=
KY821 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF7MZ2pKSzVyPUGwN|YvODRizszN M3XvO3NCVkeHUh?=
P31-FUJ M1\zW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHLKe5lKSzVyPUGxNVIvPzVizszN NEjxZmFUSU6JRWK=
COLO-824 MlHDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYDGUoQxUUN3ME2xNlYyNjd6IN88US=> NVztb2N5W0GQR1XS
U-698-M MlHYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIr2blNKSzVyPUKyOlIvOTVizszN NEjkfmxUSU6JRWK=
TE-441-T MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWfsWGtuUUN3ME2yOVIyNjdizszN M1H0OnNCVkeHUh?=
IMR-5 M1XQfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3fnbmlEPTB;M{SwPU43OiEQvF2= NWna[lllW0GQR1XS
NCI-H1838 M3Tlb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWPJR|UxRTRzOE[uN|Ih|ryP NFHoNVJUSU6JRWK=

... Click to View More Cell Line Experimental Data
In vivo The anticancer effects of bortezomib as a single agent have been demonstrated in xenograft models of multiple myeloma, adult T-cell leukemia, lung, breast, prostate, pancreatic, head and neck, and colon cancer, and in melanoma. [2] Oral bortezomib 1.0 mg/ kg daily for 18 days causes tumor growth delays, as well as a decrease in the number of metastases in the Lewis lung cancer model. Bortezomib at a single dose of up to 5 mg/kg significantly decreased the surviving fraction of breast tumor cells. Bortezomib 1.0 mg/kg administrated weekly for 4 weeks reduces tumor growth by 60% in murine xenograft models of prostate cancer. 1.0 mg/kg Bortezomib administration for 4 weeks results in a 72% or 84% reduction in pancreatic cancer murine xenografts growth, as well as an increase in tumor cell apoptosis. 1.0 mg/kg Bortezomib treatment results in significant inhibition of human plasmacytoma xenograft growth, increase in tumor cells apoptosis and overall survival, and a decrease in tumor angiogenesis. [3]

Protocol

Kinase Assay:

[4]
+ Expand

Kinetic Methods:

In a typical kinetic run, 2.00 mL of assay buffer (20 mM HEPES, 0.5 mM EDTA, 0.035% SDS, pH 7.8) and Suc-Leu-Leu-Val-Tyr-AMC in DMSO are added to a 3 mL fluorescence cuvette, and the cuvette is placed in the jacketed cell holder of a fluorescence spectrophotometer. Reaction temperature is maintained at 37℃ by a circulating water bath. After the reaction solution has reached thermal equilibrium (5 minutes), 1 μL−10 μL of the stock enzyme solution is added to the cuvette. Reaction progress is monitored by the increase in fluorescence emission at 440 nm (λex= 380 nm) that accompanies cleavage of AMC from peptide-AMC substrates.
Cell Research:

[5]
+ Expand
  • Cell lines: Human multiple myeloma cells line U266
  • Concentrations: ~10 μM
  • Incubation Time: 2 days
  • Method:

    The inhibitory effect of Bortezomib on cell growth is assessed by measuring MTT dye absorbance of the cells. Cells from 48-hour cultures are pulsed with 10 μL of 5 mg/mL MTT to each well for the last 4 hour of 48-hour cultures, followed by 100 μL of isopropanol containing 0.04 N HCl. Absorbance is measured at 570 nm using a spectrophotometer.


    (Only for Reference)
Animal Research:

[3]
+ Expand
  • Animal Models: Human plasmacytoma xenografts RPMI 8226
  • Formulation: Saline
  • Dosages: 1 mg/kg
  • Administration: i.v. twice weekly for 4 weeks, then once weekly
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 76 mg/mL (197.79 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
2% DMSO+30% PEG 300+ddH2O
For best results, use promptly after mixing. 		5mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 384.24
Formula

C19H25BN4O4
CAS No. 179324-69-7
Storage powder
in solvent
Synonyms LDP-341, MLM341

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT03607643 Not yet recruiting Cancer of Pancreas|Cancer of Liver|Cancer of Rectum|Cancer of Colon|Cancer Gall Bladder|Myeloma Multiple|Glioblastoma Multiforme Leaf Vertical Inc. January 15 2019 Phase 1|Phase 2
NCT03701321 Not yet recruiting Recurrent Plasma Cell Myeloma|Refractory Plasma Cell Myeloma National Cancer Institute (NCI) January 25 2019 Phase 1|Phase 2
NCT03729804 Not yet recruiting Multiple Myeloma University of Chicago December 24 2018 Phase 3
NCT03651128 Not yet recruiting Multiple Myeloma Celgene November 30 2018 Phase 3
NCT03737136 Recruiting Antibody-mediated Rejection Shahid Beheshti University of Medical Sciences November 1 2018 Not Applicable
NCT03652064 Not yet recruiting Multiple Myeloma Janssen Research & Development LLC November 26 2018 Phase 3

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    On your website, it is mentioned that Bortezomib should be prepared at a concentration of 5 mg/ml in 2% DMSO/30% PEG300/ddH2O for in vivo use. But on the product sheet we received with the compound, it is mentioned: 5mg/ml in 0.5% methylcellulose, 0.2% tween 80. So which is the correct preparation buffer?

  • Answer:

    S1013 Bortezomib in 2% DMSO+30% PEG 300+ddH2O at 5 mg/ml is a clear solution, and it in 0.5% methylcellulose+0.2% Tween 80 is a suspension. Please choose the suitable vehicle according to your administration route. When you prepare the clear solution, please dissolve Bortezomib in DMSO first, make sure it dissolves well, warm it up to 45 degree and/or sonicate if necessary, then add PEG, mix well, and finally add water.

selleck catalog

Proteasome Signaling Pathway Map

Proteasome Inhibitors with Unique Features

  • Pan Proteasome Inhibitor

    Ixazomib (MLN2238) : β5 site, IC50=3.4 nM; β1 site, IC50=31 nM; β2 site, IC50=3500 nM.

  • FDA-approved Proteasome Inhibitor

    Carfilzomib (PR-171) : Approved by FDA for multiple myeloma.

  • Newest Proteasome Inhibitor

    Oprozomib (ONX 0912) : Orally bioavailable inhibitor for CT-L activity of 20S proteasome β5/LMP7 with IC50 of 36 nM/82 nM.

Related Proteasome Products3

  • VR23 New

    VR23 is a potent proteasome inhibitor with IC50 of 1 nM, 50-100 nM, and 3 μM for trypsin-like proteasomes, chymotrypsin-like proteasomes, and caspase-like proteasomes, respectively.

  • Calpeptin New

    Calpeptin is a potent, cell-permeable calpain inhibitor with ID50 of 52 nM, 34 nM, 138 nM, and 40 nM for Calpain I (porcine erythrocytes), Calpain II (porcine kidney), Papainb, and Calpain I (human platelets), respectively.

  • Marimastat (BB-2516) New

    Marimastat (BB-2516) is a broad spectrum matrix metalloprotease (MMP) inhibitor for MMP-9, MMP-1, MMP-2, MMP-14 and MMP-7 with IC50 of 3 nM, 5 nM, 6 nM, 9 nM and 13 nM, respectively. Phase 3.

  • MG-132

    MG132 is a potent cell-permeable proteasome and calpain inhibitor with IC50s of 0.1 and 1.2 μM for the inhibition of proteasome and calpain, respectively.

  • Carfilzomib (PR-171)

    Carfilzomib (PR-171) is an irreversible proteasome inhibitor with IC50 of <5 nM in ANBL-6 cells, displayed preferential in vitro inhibitory potency against the ChT-L activity in the β5 subunit, but little or no effect on the PGPH and T-L activities.

  • Ixazomib (MLN2238)

    MLN2238 inhibits the chymotrypsin-like proteolytic (β5) site of the 20S proteasome with IC50 and Ki of 3.4 nM and 0.93 nM in cell-free assays, respectively, also inhibits the caspase-like (β1) and trypsin-like (β2) proteolytic sites, with IC50 of 31 and 3500 nM. Phase 3.

    Features:A first-in-class proteasome inhibitor that has improved pharmacokinetics (PK), pharmacodynamics(PD), and antitumor activity in preclinical studies.

  • Ixazomib Citrate (MLN9708)

    Ixazomib Citrate (MLN9708) immediately hydrolyzed to MLN2238, the biologically active form, on exposure to aqueous solutions or plasma. MLN2238 inhibits the chymotrypsin-like proteolytic (β5) site of the 20S proteasome with IC50/Ki of 3.4 nM/0.93 nM in cell-free assays, less potent to β1 and little activity to β2. Phase 3.

    Features:The 1st oral proteasome inhibitor in early stage clinical trials for Multiple Myeloma.

  • Celastrol

    Celastrol is a potent proteasome inhibitor for the chymotrypsin-like activity of a purified 20S proteasome with IC50 of 2.5 μM.

    Features:A potent antioxidant and anti-inflammatory drug.

  • Oprozomib (ONX 0912)

    Oprozomib (ONX 0912) is an orally bioavailable inhibitor for CT-L activity of 20S proteasome β5/LMP7 with IC50 of 36 nM/82 nM. Phase 1/2.

Tags: buy Bortezomib (PS-341) | Bortezomib (PS-341) supplier | purchase Bortezomib (PS-341) | Bortezomib (PS-341) cost | Bortezomib (PS-341) manufacturer | order Bortezomib (PS-341) | Bortezomib (PS-341) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID